Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Spinifex Pharmaceuticals
Spinifex Pharmaceuticals
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Spinifex Pharmaceuticals sold to Novartis
Novartis will continue to develop the company’s programmes to address neuropathic pain
Research & Development
Spinifex Pharmaceuticals makes two senior appointments in CMC team
Peter Spargo joins as SVP, CMC with Christine Richardson as Director, CMC and Nonclinical Project Manager
Research & Development
Spinifex Pharmaceuticals appoints neuroscience expert as Chief Medical Officer
Ronald Marcus joins the Australian-US biotechnology company
Regulatory
Neuropathic pain – EMA401
Pain that arises as a direct consequence of a lesion or disease affecting the somatosensory system is notoriously difficult to treat
Subscribe now